SARCLISA is now approved in combination with carfilzomib and dexamethasone (Kd) for the treatment of adult patients with relapsed or refractory multiple myeloma who have received 1 to 3 prior lines of therapy. MAT-US-2101240-v1.0-03/2021

Learn more

MAT-US-2101240-v1.0-03/2021

Printed From:

For US Healthcare Professionals Only

Full Prescribing Information Important Safety Information Link to Patient Site

MECHANISM OF ACTION

SARCLISA Is a Multimodal Anti-CD38 mAb

Targeted binding to a specific epitope
induces distinct antitumor activity^1-3

Mechanism of action: SARCLISA inhibits CD38 enzymatic activity.

Mechanism of action: SARCLISA triggers cell death through tumor cell targeting.

Mechanism of action: SARCLISA enhances the immune system.

Mechanism of action: SARCLISA directly destroys myeloma cells through apoptosis.

Back to topTop CareASSIST Patient Support

References: 1. SARCLISA [prescribing information]. Bridgewater, NJ: sanofi-aventis U.S. LLC. 2. Martin TG, Corzo K, Chiron M, et al. Therapeutic opportunities with pharmacological inhibition of CD38 with isatuximab. Cells. 2019;8(12):E1522. doi:10.3390/cells8121522. 3. Attal M, Richardson PG, Rajkumar SV, et al; on behalf of the ICARIA-MM study group. Isatuximab plus pomalidomide and low-dose dexamethasone versus pomalidomide and low-dose dexamethasone in patients with relapsed and refractory multiple myeloma (ICARIA-MM): a randomised, multicentre, open-label, phase 3 study. Lancet. 2019;394(10214):2096-2107.

SARCLISA Is a Multimodal Anti-CD38 mAb

Targeted binding to a specific epitope
induces distinct antitumor activity^1-3

CONTRAINDICATIONS

WARNINGS AND PRECAUTIONS

ADVERSE REACTIONS

CONTRAINDICATIONS

WARNINGS AND PRECAUTIONS

ADVERSE REACTIONS

SARCLISA Is a Multimodal Anti-CD38 mAb

Targeted binding to a specific epitope induces distinct antitumor activity1-3

Targeted binding to a specific epitope
induces distinct antitumor activity^1-3